We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dextroamphetamine-Cocaine Behavioral Intervention - 5

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000308
First Posted: September 21, 1999
Last Update Posted: January 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
University of Texas
Information provided by:
National Institute on Drug Abuse (NIDA)
  Purpose
The purpose of this study is to examine dextroamphetamine-cocaine behavioral intervention in cocaine dependent patients.

Condition Intervention Phase
Cocaine-Related Disorders Drug: Dextroamphetamine Drug: D-amphetamine Drug: placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: D-amphetamine-Cocaine Behavioral Intervention

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Verifiable cocaine abstinence [ Time Frame: 16 weeks of study ]

Enrollment: 54
Study Start Date: September 1995
Study Completion Date: September 2000
Primary Completion Date: September 2000 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
Drug: Dextroamphetamine
15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
Experimental: 2
30 mg of d-amphetamine for first 8 weeks of study and 60 mg for the second 8 weeks
Drug: D-amphetamine
15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
Experimental: 3
placebo
Drug: placebo
placebo

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000308


Locations
United States, Texas
University of Texas Health Science Center
Houston, Texas, United States, 77225
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
University of Texas
Investigators
Principal Investigator: John Grabowski, Ph.D. University of Texas
  More Information

Responsible Party: F. Gerard Moeller, M.D., University of Texas Medical School at Houston
ClinicalTrials.gov Identifier: NCT00000308     History of Changes
Other Study ID Numbers: NIDA-09262-5
P50-09262-5
First Submitted: September 20, 1999
First Posted: September 21, 1999
Last Update Posted: January 12, 2017
Last Verified: October 2016

Keywords provided by National Institute on Drug Abuse (NIDA):
cocaine dependence

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Cocaine
Amphetamine
Dextroamphetamine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Central Nervous System Stimulants
Sympathomimetics
Autonomic Agents
Adrenergic Agents
Adrenergic Uptake Inhibitors